U.S. VASOPRESSIN MARKET ANALYSIS

U.S. Vasopressin Market, by Type (Intravenous Injection, Intramuscular Injection, Subcutaneous Injection, and Others), by Application (Anti-diuretic Hormone Deficiency, Gastrointestinal Bleeding, Vasodilatory Shock, Ventricular Tachycardia, and Fibrillation), and by End User (Hospitals, Dental Clinics, and Others) - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2028

Published In : Mar 2022
Code : CMI4985
Pages :120
Formats :
Excel and PDF
Industry : Pharmaceutical

U.S. Vasopressin MarketSize and Trends

The U.S. vasopressin market is estimated to be valued at US$ 894.6 Mn in 2021, and is expected to exhibit a CAGR of 14.7% over the forecast period (2021-2028).

Figure 1: U.S. Vasopressin Market Share (%) Analysis, By Type, 2021

Increasing regulatory approvals of vasopressin is the major factor that is expected to drive growth of the U.S. vasopressin market over the forecast period.

Increasing regulatory approvals of vasopressin in the U.S. is expected to be the major factor driving the growth of U.S. vasopressin market over the forecast period. For instance, in December 2021, Eagle Pharmaceuticals, Inc., a U.S.-based pharmaceutical company, announced that the U.S. Food and Drug Administration approved the company’s abbreviated new drug application ‘ANDA’ for vasopressin.

U.S. Vasopressin Market Report Snapshots